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Cell-cycle transition from the G2 phase into mitosis
is regulated by the cyclin-dependent protein kinase 1
(CDK1) in complex with cyclin B. CDK1 activity is
controlled by both inhibitory phosphorylation, catalysed
by the Myt1 and Wee1 kinases, and activating depho-
sphorylation, mediated by the CDC25 dual-speciﬁcity
phosphatase family members. In somatic cells, Wee1 is
downregulated by phosphorylation and ubiquitin-mediated
degradation to ensure rapid activation of CDK1 at the
beginning of M phase. Here, we show that downregulation
of the regulatory b-subunit of protein kinase CK2 by RNA
interference results in delayed cell-cycle progression at the
onset of mitosis. Knockdown of CK2b causes stabilization
of Wee1 and increased phosphorylation of CDK1 at the
inhibitory Tyr15. PLK1–Wee1 association is an essential
event in the degradation of Wee1 in unperturbed cell cycle.
We have found that CK2b participates in PLK1–Wee1
complex formation whereas its cellular depletion leads to
disruption of PLK1–Wee1 interaction and reduced Wee1
phosphorylation at Ser53 and 121. The data reported here
reinforce the notion that CK2b has functions that are
independent of its role as the CK2 regulatory subunit,
identifying it as a new component of signaling pathways
that regulate cell-cycle progression at the entry of mitosis.
Oncogene (2008) 27, 4986–4997; doi:10.1038/onc.2008.146;
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Introduction
Protein kinase CK2 is a serine/threonine kinase highly
conserved throughout evolution and is ubiquitously
expressed in eukaryotic cells. Traditionally, CK2 is
described as a constitutively active tetrameric enzyme
composed of two catalytic a and/or a0 subunits and two
regulatory b subunits. More recently, the classical view
of CK2 as a stable tetrameric complex has been
modiﬁed, suggesting that the individual subunits may
have independent functions and they may be asymme-
trically distributed inside the cell (reviewed in Litchﬁeld,
2003; Bibby and Litchﬁeld 2005). CK2 is involved in
various intracellular processes ranging from regulation
of transcription and DNA replication to proliferation,
survival and differentiation. The involvement of CK2 in
the regulation of cell-cycle progression has been
explored in lower as well as higher eukaryotes. Genetic
studies in yeast indicated that CK2 regulates both the
G1/S and G2/M transitions (reviewed in Glover, 1998).
In this respect, Toczyski et al. (1997), by exploring the
yeast DNA damage checkpoint regulation, demon-
strated the involvement of CK2b and Cdc5 in the
adaptation to DNA damage in budding yeast. Evidence
that CK2 plays a role in cell-cycle regulation in
mammalian cells comes from ﬁndings that CK2 is
associated with the mitotic spindle and centrosomes and
interacts with and/or phosphorylates numerous cell-
cycle regulatory proteins including Pin1, topoisomerase
II, cdc34 and cyclin-dependent kinase 1 (CDK1;
reviewed in Faust and Montenarh, 2000; Litchﬁeld,
2003). Recent results have also indicated the involve-
ment of CK2 in the cellular decision of life and death in
response to ionizing radiation damage (Yamane and
Kinsella, 2005).
Cell-cycle progression is tightly regulated by a
plethora of proteins that act in order to preserve the
integrity of the genetic information to be transferred to
daughter cells. Entry into mitosis requires the involve-
ment of CDK1 that becomes active following its
association with cyclin B and phosphorylation on a
threonine residue located in the conserved T-loop
domain. During interphase, CDK1 is maintained in an
inactive state by phosphorylation at two amino-acid
residues (that is, Thr14 and Tyr15) located within the so-
called ATP-binding loop. Myt1 and Wee1 protein
kinases mediate the phosphorylation of CDK1 at the
aforementioned residues, whereas the CDC25 dual-
speciﬁcity protein phosphatase family members catalyse
the activating dephosphorylation at the same sites
(reviewed in Pines, 1999). Entry into mitosis involves a
remarkably high number of kinases and phosphatases
and it is regulated by both positive and negative feed
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back loops. Interestingly, Wee1 and CDC25 proteins are
similarly regulated despite their inhibiting and activating
roles on mitotic entry, respectively. Their activities
oscillate in opposition to one another but their turnover
is regulated by phosphorylation at speciﬁc amino acids
during cell-cycle progression. CDC25A is an unstable
protein that is thought to play a role in both G1/S and
G2/M cell-cycle transitions (reviewed in Busino et al.,
2004). In interphase, Chk1 phosphorylates CDC25A on
four different sites (Ser124, 178, 279 and 293; Srensen
et al., 2003; reviewed in Busino et al., 2004) contributing
to its rapid turnover in unperturbed cells. Upon DNA
damage, both Chk1 and Chk2 kinases contribute to
further phosphorylate CDC25A at Ser124, 178 and 293
inducing a rapid proteasome-mediated degradation of
the latter thus activating the cell-cycle G2/M checkpoint
(Srensen et al., 2003). Wee1 becomes inactive at the
onset of mitosis when active CDK phosphorylates it at
Ser123 (Van Vugt et al., 2004; Watanabe et al., 2004).
Phosphorylation of the aforementioned residue contri-
butes to the formation of a polo box domain (PBD)-
binding site that allows the binding of PLK1 to Wee1
with the outcome of promoting phosphorylation at
Ser53 and subsequent proteasome-mediated degrada-
tion of Wee1 (Watanabe et al., 2005).
We have recently shown that ectopic expression of
CK2b during unperturbed cell-cycle progression en-
hances the degradation of CDC25A. This effect is
mediated by Chk1 as the pharmacological inhibition of
Chk1 kinase activity and the cellular depletion of Chk1
by RNA interference, respectively, counteract the
downregulation of CDC25A induced by CK2b over-
expression. Interestingly, we also showed that the sole
depletion of CK2b by siRNA is able to enhance the
stability of the phosphatase (Kreutzer and Guerra,
2007).
In the present study, we aimed to closely investigate
the role of CK2b with respect to cell-cycle regulation at
the G2/M transition. Surprisingly, during our studies we
found that the cellular depletion of CK2b by siRNA
leads to enhanced levels of Wee1 resulting in delayed
progression into mitosis. Our data suggest an undis-
closed role of CK2b in regulating the stability of Wee1,
revealing a novel component of the complex machinery
that operates at the G2/M transition.
Results
Depletion of CK2b stabilizes CDC25A
Previously, we showed that the cellular depletion of
CK2b by short RNA duplexes (siRNA) led to a
signiﬁcant higher level of CDC25A protein (Kreutzer
and Guerra, 2007). In order to verify whether this effect
was exclusively mediated by CK2b we transfected
H1299 lung cancer cells with siRNAs directed against
the individual CK2 subunits (that is, -a, -a0 and -b) and
analysed the endogenous CDC25A protein level
(Figure 1a). Interestingly, CDC25A levels increased
not only in cells depleted of CK2b (lane 5) but also after
treatment with siRNAs against CK2a or a combination
of CK2a and CK2a0 (lanes 2 and 4) but not CK2a0 (lane
3). As CDC25C contributes to the regulation of the G2/
M cell-cycle transition, we also analyzed its expression
under the aforementioned conditions. As shown in
Figure 1a, the downregulation of the individual CK2
subunits did not affect CDC25C expression levels. The
notion that CK2a also contributes to the stability of
CDC25A could not be excluded at this point although
we noticed that the depletion of CK2a, but not CK2a0,
led to downregulation of CK2b expression (lanes 2 and
4), an effect that underlines the functional specialization
of the CK2 catalytic subunits and that we previously
attributed to the ability of CK2b to assemble with the
catalytic subunits in stable heterotetramers for preser-
ving its stability (Seeber et al., 2005). In this respect, it
has been shown that if CK2b fails to form complexes
with the catalytic subunit it undergoes rapid degrada-
tion (Lu¨scher and Litchﬁeld, 1994). To clarify the
contribution of CK2a in the stability of CDC25A, we
analysed the levels of endogenous CDC25A in cells
treated with a panel of CK2 kinase inhibitors, that is,
4,5,6,7-tetrabromo-2-azabenzimidazole (TBB), emodin
and apigenin with respect to control cells incubated with
dimethyl sulfoxide. CK2 kinase activity in whole cell
lysates from H1299 cells treated as indicated in
Figure 1b showed that all treatments were effective in
inhibiting the kinase activity of CK2. Next, western blot
analysis of protein extracts from cells treated as
described above revealed that the inhibition of CK2
did not inﬂuence the expression level of endogenous
CDC25A protein (Figure 1c), thus excluding a possible
contribution of the CK2 catalytic activity in the
regulation of CDC25A stability. On the contrary, cell
treatment with emodin lowered the expression of
CDC25A (Figure 1c, lane 3), an effect which was not
further investigated because beyond the scope of the
present paper. As a positive control, cells were also
treated with Go¨6976, a known inhibitor of Chk1 (Kohn
et al. 2003; Figure 1c, lane 5), but not of CK2
(Figure 1b), and we veriﬁed that inhibition of Chk1
kinase activity enhanced the expression of endogenous
CDC25A.
Enhanced level of CDC25A in cells depleted of CK2b does
not lead to accelerated G2/M cell-cycle transition
Although originally considered a regulator of the cell-
cycle G1/S transition, CDC25A has also been shown to
be required for cell-cycle progression from G2 to M
phase (reviewed in Boutros et al., 2006; Karlsson-
Rosenthal and Millar, 2006). Cellular exposure to a
wide variety of DNA insults leads to Chk1-mediated
CDC25A degradation triggering the G2/M checkpoint,
whereas the cellular depletion of Chk1 or overexpression
of CDC25A abrogates checkpoint arrest (Mailand et al.,
2000; Xiao et al., 2003). As treatment of cells with CK2b
siRNA led to higher levels of CDC25A, we next
investigated how CK2b might inﬂuence the G2/M
transition. As indicated in Figure 2a, cells were treated
with siRNAs against the indicated proteins and in-
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cubated with doxorubicin to induce DNA damage. As
expected, the cellular depletion of Chk1 (lane 2) led to
stabilization of CDC25A as compared to the control
experiment (lane 1). Expression of CDC25A also
increased in cells treated with CK2b and CK2a siRNAs
(lanes 3 and 4, respectively) although not to the same
extent. Given the lower expression of CDC25A in cells
depleted of CK2b and treated with doxorubicin (as
compared with cells treated with Chk1 siRNA), we
investigated whether the CDC25A level was enough to
disrupt the G2/M checkpoint induced by drug treat-
ment. As shown in Figures 2b and c, cells treated with
scramble siRNA and exposed to doxorubicin for 48 h
arrested at G2 phase whereas cells treated with Chk1-
speciﬁc siRNA (positive control) continued to prolifer-
ate showing a cell-cycle distribution similar to that of
cells treated with scramble siRNA in the absence of
doxorubicin as reported earlier (Xiao et al., 2003). When
cells transfected with CK2b siRNA were exposed to
doxorubicin, we did not observe a signiﬁcant abrogation
of G2/M checkpoint, indicating that the moderate
stabilization of CDC25A (in Figure 2a, the level of
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Figure 1 Contribution of the CK2 subunits to the stability of the CDC25A protein phosphatase. (a) H1299 cells were transfected with
siRNAs for downregulating CK2a (lane 2), CK2a0 (lane 3), CK2a and CK2a0 (lane 4) and CK2b (lane 5), respectively. Lane 1 refers to
cells transfected with a scramble siRNA (Scramble). Cell lysates were subjected to western blot analysis with the indicated antibodies.
The blot was probed with anti-b-actin antibody in order to verify equal protein loading. The values expressed in percentages below the
lane numbers refer to the densitometric analysis of the protein bands detected with anti-CDC25A antibody. The quantiﬁcation was
performed by assigning a value of 100% to the band in lane 1. (b) H1299 cells were treated for 5 h with dimethyl sulfoxide (DMSO;
Control), 25 mM TBB, 40mM emodin, 50mM apigenin and for 24 h with 300 nM Go¨6976, respectively. Total lysates (20mg) were
subjected to CK2 kinase activity with a speciﬁc CK2 peptide substrate as described in the materials and methods. The average and
standard deviation of three independent experiments are shown. (c) Cells were treated as in (a). Total lysates were subjected to SDS–
polyacrylamide gel electrophoresis (PAGE). Separated proteins were transferred to polyvinylidene diﬂuoride (PVDF) membrane by
western blot. Proteins were visualized by probing the membranes with the indicated monoclonal antibodies. Data shown are
representative of three independent experiments.
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CDC25A in lane 3 is about 50% less than that in lane 2)
was not sufﬁcient to abrogate the G2 checkpoint as in
the case of Chk1 siRNA treatment. Consistent with the
notion that overexpression of CDC25A accelerates entry
into mitosis (Molinari et al., 2000; Zhao et al., 2002), we
tested whether the stabilization of CDC25A in cells
treated with CK2b siRNA affected the G2/M transition
in the absence of DNA damage (Figure 3). Cells
transfected with scramble or CK2b siRNAs were shortly
exposed to the mitotic inhibitor nocodazole to trap cells
exiting G2 and were analysed afterwards by ﬂow
cytometry. Unexpectedly, we observed delayed cell-cycle
progression (Figures 3b and c) despite stabilization of
CDC25A in CK2b-reduced cells (Figure 3a). Whereas
about 17% of the control cell population was phospho-
histone H3 (a marker of entry into mitosis) positive
after 8 h of incubation with nocodazole, only 10%
of the CK2b-depleted cells were found arrested in
mitosis at the aforementioned time point (Figures 3b
and c). While suggesting a possible role of CK2b in
G2/M transition, the data, however, were not
consistent with the observation that CDC25A becomes
stabilized in cells transfected with CK2b siRNA
(Figures 1 and 3a).
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Figure 2 The regulatory b-subunit of CK2 is dispensable for G2/M checkpoint activation. (a) H1299 cells were transfected with
scramble (lane 1), Chk1 (lane 2), CK2b (lane 3) and CK2a (lane 4) siRNAs, respectively. After 24 h from transfection, cells were
incubated with 0.25mM doxorubicin (Dox) for additional 48 h. The analysis of the indicated proteins and the densitometric analysis of
CDC25A protein bands were done as described in the legend to Figure 1. (b) Cells were treated as indicated in (a). After 48 h
of incubation with doxorubicin cells were harvested for ﬂow cytometry analysis of cell-cycle distribution. The distribution of cells in the
cell-cycle phases is indicated in the upper-left panel. Sub-G1 cell populations are indicated with an asterisk. (c) Cells from the
experiment shown in (b) were gated and their percentage was calculated according to the phases of the cell cycle. Three separate
experiments were performed and data from one representative experiment are shown.
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Knockdown of CK2b destabilizes the complex between
Wee1 and PLK1 kinases and upregulates Wee1 protein
As mentioned previously, both activating and inhibiting
phosphorylations are required for modulating CDK1
activity at the onset of mitosis. Wee1 is considered the
major kinase phosphorylating CDK1 at the Tyr15 site
(reviewed in Perry and Kornbluth, 2007). As cellular
depletion of CK2b led to delayed cell-cycle progression
at the G2/M transition, we analysed the protein
expression of Wee1 in cells transfected with various
siRNAs (Figure 4). The cellular depletion of CK2b
stabilized Wee1 (lane 5) as indicated also by the
densitometric analysis of Wee1 protein bands. Addi-
tionally, we noticed stabilization of Wee1 in cells
transfected with CK2a siRNA (lane 3) but, as men-
tioned earlier, we believe that this is an indirect effect
due to the CK2a knockdown-dependent destabilization
of CK2b. The stabilization of Wee1 was also accom-
panied by a higher phosphorylation of CDK1 at Tyr15
as also indicated by the densitometric analysis of
phospho-CDK1 protein bands (lanes 3 and 5). A kinase
assay revealed a 40% decrease CDK1 activity in CK2b-
depleted cells as compared to cells transfected with
scramble siRNA (results not shown).
The aforementioned data suggest that the higher level
of Wee1 observed in cells transfected with CK2b
siRNA, might be responsible for the observed delayed
cell-cycle G2/M transition. Additionally, these data raise
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Figure 3 The cellular depletion of CK2b stabilizes CDC25A but leads to delayed cell-cycle progression at the onset of mitosis.
(a) H1299 cells were transfected with the indicated siRNAs for 72 h. Cell lysates were analysed by western blot probing the membranes
with the indicated antibodies. The intensity of the protein bands detected with anti-CDC25A antibody was quantiﬁed in percentage by
densitometric analysis by assigning a value of 100% to the band in lane 1. (b) Cells were transfected with scramble and CK2b siRNAs,
respectively, for 48 h prior to treatment with 200 ng/ml nocodazole for the indicated time points. Next, cells were ﬁxed and
subsequently stained with propidium iodide and anti-phospho-histone H3 (Ser10) antibody conjugated with Alexa Fluor 488 for ﬂow
cytometry analysis. The percentage of mitotic cells from the total amount of cells was quantiﬁed by Cell Quest Pro analysis software
gating the appropriate cell populations. (c) The percentage of mitotic cells from the experiment described in (b) was plotted against
incubation time in the presence of 200 ng/ml nocodazole. Experiments were performed three times obtaining similar results.
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questions as to how Wee1 stabilization is achieved in
cells depleted of CK2b. Wee1 is inactivated at the onset
of mitosis by both phosphorylation and degradation in
human somatic cells whereas in lower eukaryotes it is
regulated either at the protein level as in the case of
budding yeast, or mainly by phosphorylation as in
ﬁssion yeast (Coleman et al., 1993; Parker et al., 1993;
Tang et al., 1993; Wu and Russell, 1993; Sia et al., 1998).
Evidence indicates that although Wee1 lacks a canonical
b-TrCP binding consensus sequence for ubiquitin-
mediated degradation, phosphorylation at three serine
residues, namely Ser53, 121 and 123, were found to be
required for b-TrCP recognition (Watanabe et al., 2004,
2005). Interestingly, it has been reported that CDK,
PLK1 and CK2 kinases create the two b-TrCP-
phosphodegrons that are responsible of Wee1 degrada-
tion at the onset of mitosis (Watanabe et al., 2005).
Therefore, to explore the possible involvement of these
enzymes we analysed whether the higher expression level
of Wee1 reﬂected a downregulation of PLK1 at the
protein and/or at the activity levels. We synchronized
cells and looked at the expression- and activity levels of
PLK1 at the different phases of the cell cycle (Figures
5a, b and c). As shown in Figure 5, PLK1 expression
and activity increase at the onset of mitosis that occurs
8 h after release from the aphidicolin-induced G1/S
arrest and remain high during mitosis. Next, we
analysed whether CK2b knockdown affected the abun-
dance of PLK1 (Figure 5d) in synchronized cells
harvested at 10h after release from the G1/S block and
arrested in mitosis, respectively. Additionally, we im-
munoprecipitated PLK1 from cells treated, as indicated
above, and tested the kinase activity (Figure 5e). Based
on the obtained results, we excluded the possibility that
the accumulation of Wee1 observed in cells transfected
with CK2b siRNA, reﬂected decreased expression and/or
activity of PLK1. A possible direct CK2b-mediated effect
on PLK1 was also excluded by in vitro experiments,
where the activity of PLK1 was tested in the presence of
increasing amounts of recombinant CK2b, showing that
CK2b does not modulate the activity of PLK1
(Figure 5f). Next, a plausible hypothesis was to assume
a direct involvement of CK2 in the observed stabilization
of Wee1 in cells depleted of CK2b. We reasoned that
cellular depletion of CK2b would lower the kinase
activity of endogenous CK2 required for Wee1 phos-
phorylation at Ser121, which promotes the b-TrCP-
dependent destabilization of Wee1 (Watanabe et al.,
2005). Indeed, we observed approximately 50% reduction
in CK2 kinase activity in both asynchronous and
synchronized cells transfected with CK2b siRNA
(Figure 6a). Cells, treated as described in the legend to
Figure 6b, were analysed for the expression of the
indicated proteins and subjected to co-immunoprecipita-
tion employing anti-PLK1 antibody. Transfection of cells
with CK2b siRNA resulted in a shift in Wee1 electro-
phoretic mobility on SDS–polyacylamide gels (Figure 6b,
lanes 4–6). In Figure 6c, in asynchronous cells (lanes 2
and 5) and in cells arrested in mitosis (lanes 4 and 7), we
detected a slight interaction between PLK1 and Wee1. In
contrast, in synchronized cells harvested at 10h after
release from the G1/S block and transfected with
scramble siRNA, we observed a strong interaction
among CK2b, PLK1 and Wee1 (lane 3) indicating that
CK2b participates in the Wee1–PLK1 complex forma-
tion at the onset of mitosis. Strikingly, we did not observe
any protein–protein association in synchronized cells
transfected with CK2b siRNA (lane 6). We, then,
examined whether CK2b affects the binding of PBD
motif to Wee1 and thus, Wee1 phosphorylation at
Ser123. Results shown in Figure 7a demonstrated that
the PBD-mediated binding of PLK1 to Wee1 is not
regulated by CK2b. The phosphorylation of Wee1 in
lysates from cells treated as described in Figure 6b was
analysed with respect to phosphorylation at Ser53 and
121 (Figure 7b). While the Ser53 phosphorylation was
slightly lowered, the Ser121 phosphorylation was drama-
tically reduced by the CK2b knockdown when compared
with the total Wee1 level (lanes 4–6). As both these
phosphorylation events are important for the binding of
b-TrCP to Wee1, we conclude that the reduction in
phosphorylation by the CK2b depletion seems to be
responsible for the stabilization of Wee1 in vivo.
Discussion
Cell-cycle progression is spatially and timely regulated
by cyclin-dependent kinases, which are subjected to a
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Figure 4 Reduced level of CK2b stabilizes Wee1 kinase. H1299
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complex post-translational regulation in a stepwise
fashion. While surveillance pathways provide informa-
tion on the integrity of the genome and/or the general
well being of the cells, the inﬂuence exerted on CDKs by
positive and negative effectors drives cellular decisions,
such as normal cell-cycle progression or activation of
checkpoints in response to DNA damage. At the G2/M
transition, inhibition of CDK1 is mediated by Wee1-
and Myt1-dependent phosphorylations, whereas its
activation is made possible by the involvement of
CDC25 phosphatases such as CDC25A. Thus, the
delicate balance between the expression and activity of
CDC25s, Wee1 and Myt1 is crucial in the modulation of
CDK1 activity at the onset of mitosis.
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The data presented in this study show that in an
unperturbed cell cycle, alteration in the level of CK2b
inﬂuences the expression of proteins that play key roles
in the modulation of the G2/M transition. Stabilization
of CDC25A is observed in cells transfected with CK2b
siRNA but it appears that CK2 kinase activity is not
directly involved in the upregulation of the aforemen-
tioned phosphatase. Based on previous studies on
cellular effects induced by CDC25A overexpression,
we anticipated that stabilization of CDC25A would lead
to unscheduled mitosis in cells depleted of CK2b.
Unexpectedly, one of the most remarkable results in
this study is the fact that upregulation of CDC25A does
not lead to accelerated entry into mitosis. Following
CK2b siRNA treatment, the observed delayed cell-cycle
progression may be attributed to the unchanged
expression of CDC25C, which contributes to the
regulation of the G2/M transition, and also to the
stabilization of Wee1 that preserves the inhibitory
phosphorylation of CDK1. In this respect, it has been
reported that the activity of Wee1 exceeds that of
CDC25s in G2 phase and that AKT promotes the G2/M
transition by phosphorylation-dependent 14-3-3y bind-
ing and cytoplasmic localization of Wee1 (Katayama
et al., 2005). The sum of these effects might explain why
in cells transfected with CK2b siRNA the stabilization
of CDC25A does not accelerate the entry into mitosis as
initially postulated. Stabilization of CDC25A was also
seen in cells treated with doxorubicin and transfected
with CK2b siRNA although not to the same extent as in
cells depleted of Chk1. Downregulation of Chk1 was
found to abrogate the doxorubicin induced G2 check-
point as a consequence of CDC25A stabilization,
whereas the same effect was not observed in cells treated
with CK2b siRNA. This suggests that a certain
CDC25A threshold level might be required for the G2
checkpoint abrogation, which can be reached in Chk1
siRNA-treated cells but not in CK2b-deﬁcient cells.
An intriguing question that we addressed during our
study is how Wee1 stability is achieved. Based on the
current knowledge on the regulation of Wee1 (Wata-
nabe et al., 2005), we speculated that knockdown of
CK2b would negatively affect the activity and/or
expression levels of PLK1 contributing to the observed
stabilization of Wee1. Based on our results, we excluded
a direct involvement of PLK1 in the observed phenotype
and we, instead, came up with a model showing that
components of distinct pathways contribute to stabilize
Wee1 in cells depleted of CK2b (Figure 8). Expression
of Wee1 mutated at Ser123 leads to disruption of
PLK1–Wee1 association (Watanabe et al., 2005). As a
similar effect is observed in cells depleted of CK2b, this
indicates that other Wee1–protein domains, targeted by
CK2b, might contribute to PLK1 binding. Previous
observations implicated CK2 kinase activity in the
regulation of Wee1 stability at the onset of mitosis
(Watanabe et al., 2005). Our data add new insights into
the mechanism of Wee1 regulation uncovering an
unprecedented role of the CK2 regulatory b-subunit
by affecting the phosphorylation of Wee1 at Ser53 and
121. Speciﬁcally, whereas reduction of Wee1 phosphor-
ylation at Ser121 can be attributed to the lower CK2
kinase activity seen in cells with reduced CK2b
expression, decreased phosphorylation at Ser53 may be
the result of attenuated Wee1–PLK1 interaction seen
under the aforementioned treatment conditions. Nu-
merous studies have reported evidence for the unba-
lanced expression of the catalytic and regulatory CK2
subunits in a variety of tissues (reviewed in Bibby and
Litchﬁeld, 2005). The fact that aberrant high expression
levels of CK2b relative to CK2a have been observed in
tumors (Stalter et al., 1994; Timofeeva et al., 2006) and
isolated CK2b has been shown in cells (Lu¨scher and
Litchﬁeld, 1994; Guerra et al., 1999) supports the notion
that CK2b may be able to modulate the expression of
critical regulators of CDK1/cyclin B activity thereby
controlling mitotic entry in a CK2-independent fashion.
At the onset of mitosis, CDK phosphorylates Wee1 at
Ser123 and this event promotes the subsequent CK2-
catalysed phosphorylation of Wee1 at Ser121 creating a
phosphodegron. Phosphorylation at Ser123 creates a
PBD-binding domain that favors the interaction of
PLK1 with Wee1 and the subsequent PLK1-catalysed
phosphorylation of Wee1 at Ser53. This latter event
Figure 5 CK2b does not inﬂuence the activity of PLK1 kinase. (a) H1299 cells were synchronized as described in materials and
methods. They were released from the G1/S block and then harvested at the indicated time points. Next, cells were ﬁxed and stained
with propidium iodide for cell-cycle analysis by ﬂow cytometry. The cell-cycle proﬁles of asynchronous (As) or nocodazole-treated cells
(Noc) are also shown. (b) Cell lysates were subjected to immunoblot analysis with the indicated antibodies. Equal protein loading was
veriﬁed by probing the western blot membranes with monoclonal anti-b-actin antibody. (c) Cell lysates from synchronized cells
harvested after release from the G1/S block at the indicated time were subjected to immunoprecipitation with rabbit monoclonal anti-
PLK1 antibody. The immunoprecipitates were used for the determination of PLK1 kinase activity using casein as substrate. Bar 1 (),
refers to the activity of PLK1 tested in the absence of substrate. The numbers are expressed in percentage by assigning a value of 100%
to the activity of PLK1 in cells treated with nocodazole. (d) Cell lysates from asynchronous (lanes 1 and 4) and synchronized cells
harvested after 10 h (lanes 2 and 5) or 12 h in the presence of nocodazole (lanes 3 and 6) after release from the G1/S block, respectively,
were subjected to western blot and probed with the indicated antibodies. The cells were transfected with scramble siRNA (lanes 1–3) or
CK2b siRNA (lanes 4–6). (e) Cell lysates from cells treated as in (d) were subjected to immunoprecipitation with rabbit monoclonal
anti-PLK1 antibody. Lane 1 shows a negative control () where cell extract was subjected to immunoprecipitation with a control
serum. The immunoprecipitates were used for the determination of PLK1 kinase activity using GST-tagged MDM2(203282) as
substrate. The activity is expressed in percentage by assigning a value of 100% to the PLK1 activity in cells treated with nocodazole
(lane 4). Lane 8* refers to the kinase activity of immunoprecipitated PLK1 in the presence of mutant GST-tagged MDM2(203282)
where the PLK1 major phosphorylation site (that is, serine 260) has been mutated to alanine. (f) In vitro PLK1 kinase assay was
performed in the presence of 1 pmol recombinant PLK1 (lane 1) or 1 pmol recombinant PLK1 and increasing amounts of recombinant
CK2b (lane 2, 0.5 pmol; lane 3, 1 pmol; lane 4, 2 pmol; lane 5, 5 pmol; lane 6, 10 pmol).
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promotes the formation of a second phosphodegron
promoting the ubiquitin-mediated degradation of Wee1.
At present, we cannot exclude the possibility that
downregulation of CK2bmight also negatively inﬂuence
components of the ubiquitylation machinery resulting in
stabilization of Wee1 kinase.
Stabilization of Wee1 and delayed cell-cycle progres-
sion may have important implications for the pathogen-
esis of cancer. Promoting Wee1 stability by CK2b
downregulation might be important for maintaining an
interphase state as long as cell-cycle checkpoints, which
operate to control the state of CDK1 tyrosine phos-
phorylation, are activated. The present study establishes
a previously unrecognized unique role of CK2b in
contributing to the timing of entry into mitosis in
mammalian cells. Future studies will certainly provide
further insights into the impact of CK2b downregula-
tion on the pathways that regulate the G2/M transition
in normal cell-cycle progression.
Materials and methods
Cell culture conditions and reagents
H1299 cells were obtained from the American Type Culture
Collection (Rockville, MD, USA) and cultured in Roswell
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Figure 6 Cellular depletion of CK2b disrupts the complex
between PLK1 and Wee1 at the G2/M transition. (a) Whole lysates
(10mg) from H1299 cells left asynchronous (bars 1 and 4) or
released from the G1/S block and harvested after 10 h (bars 2 and 5)
or 12 h in the presence of nocodazole (bars 3 and 6), respectively,
were subjected to CK2 kinase activity with a speciﬁc CK2 peptide
substrate as described in Materials and methods. The average and
standard deviation of three independent experiments are shown.
(b) Whole lysates from cells treated as in (a) were analysed by
western blot probing the membranes with the indicated antibodies.
The cells were transfected with scramble siRNA (lanes 1–3) or
CK2b siRNA (lanes 4–6) 12 h prior to synchronization. (c) Whole
lysates from cells treated as in (a) were subjected to immunopre-
cipitation with rabbit monoclonal anti-PLK1 antibody (lanes 2–7).
Lane 1 is a control experiment () were lysate from synchronized
cells harvested after 10 h from the G1/S block was subjected to
immunoprecipitation in the presence of control serum. Immuno-
precipitates were then analysed by western blot probing the
membranes with the indicated monoclonal antibodies.
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Figure 7 CK2b inﬂuences the stability of Wee1 through Wee1
phosphorylation at Ser53 and 121. (a) Wild-type (Wt) GST-PBD
and its mutant (Mt) form (H538A/K540M) were expressed in
bacteria as reported in (Watanabe et al., 2005). Bacteria lysates
were combined with whole extracts from synchronized H1299 cells
overexpressing wild-type Wee1 harvested at 10 h after release from
G1/S arrest. 12 h before transfection with plasmid DNA expressing
wild-type Wee1, cells were transfected with either scramble siRNA
(lanes 2, 4 and 7) or CK2b siRNA (lanes 5 and 8). PBDwt and -mt
were precipitated by adding glutathione sepharose beads to the
mixture as described in (Watanabe et al., 2005). Lanes 1 and 2 are
control experiments where whole cell extracts were either mixed
with recombinant puriﬁed GST (lane 1) or directly added to the
sonication buffer containing the beads (lane 2). Lanes 3 and 6 are
also control experiments where GST-PBDwt and GST-PBDmt
were added to the sonication buffer containing the beads in the
absence of cell lysates, respectively. (b) Level of Wee1 and its
phosphorylation at Ser53 and 121, respectively, were analysed with
the indicated antibodies by western blot of total lysates from cells
treated as described in Figure 6b.
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Park Memorial Institute medium (RPMI; Gibco, Taastrup,
Denmark) supplemented with 10% fetal bovine serum
in a humidiﬁed incubator at 37 1C and in 5% CO2. Cell-cycle
synchronization was achieved by starving the cells in the
absence of serum for 24 h. Subsequently, fresh medium
was added and cells were cultured in the presence of 3mg/ml
aphidicolin (Calbiochem, Nottingham, UK). After 24 h,
cells were extensively washed with phosphate buffered saline
(PBS) and released from G1/S arrest by adding fresh culture
medium. Cells were harvested at various times as indicated in
the ﬁgure legends. Where indicated, 200 ng/ml nocodazole
(Calbiochem) was added 1 h after release from the block
at the G1/S interphase and mitotic cells were collected as
indicated. For inhibition of endogenous CK2, cells were
incubated for 5 h with 25 mM TBB, 40 mM emodin and 50mM
apigenin (all from Calbiochem), respectively. Pharmaco-
logical inhibition of Chk1 kinase was performed by incubating
the cells with 300 nM Go¨6976 (Calbiochem) for 24 h.
Induction of DNA damage was induced by incuba-
ting the cells with 250 nM doxorubicin (Calbiochem)
for 48 h.
siRNA experiments
The silencing of CK2a expression was achieved by transfecting
cells with the following oligonucleotide sequence: 50-GAU
GACUACCAGCUGGUUCdTdT-30. The expression of
CK2a0 was silenced by transfecting cells with the following
sequence: 50-CAGUCUGAGGAGCCGCGAGdTdT-30. A set
of four siRNA duplexes directed against CK2b and Chk1
(ON-TARGET plus SMARTpools), respectively, were em-
ployed for downregulating the expression of the aforemen-
tioned proteins. Control experiments were performed
employing a scramble oligonucleotide sequence: 50-GAAGC
AGUCGCAGUGAAGAdTdT-30. All siRNAs were purchased
from Dharmacon (Lafayette, CO, USA). Cells were transfected
with Lipofectamine 2000 (Invitrogen, Paisley, UK) for up to 72h
following the manufacturer’s recommendations.
Cell-cycle analysis
H1299 cells were collected after various treatments by
trypsinization, washed with PBS, ﬁxed overnight in 70%
ethanol at 20 1C, incubated for 30min with 20 mg/ml
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Figure 8 Model of the proposed inﬂuence of CK2b on G2/M transition. Active cyclin B-CDK1 kinase promotes G2/M transition. The
activity of CDK1 is negatively controlled by Wee1-dependent phosphorylation and positively regulated by CDC25A-dependent
dephosphorylation. The stability of Wee1 is controlled by a series of phosphorylations, including phosphorylation by CK2, which
creates the ﬁrst phosphodegron (pSer121), responsible for Wee1 instability during interphase (Watanabe et al., 2004, 2005). At the
onset of M phase, stabilized PLK1 binds to CDK-mediated phosphorylated Wee1. Subsequently, PLK1 phosphorylates Wee1 at Ser53
(that is, pSer53 creates the second phosphodegron) leading to ubiquitination and proteasome-dependent degradation of Wee1. The
CDC25A phosphatase is also a target of CDK1 albeit the CDK1-dependent phosphorylation leads to CDC25A stabilization. Upon
DNA damage, CDC25A is subjected to multiple phosphorylations from Chk1 and other protein kinases (‘PK’), including Chk2 and
p38 MAPK, leading to destabilization of the phosphatase. Disruption of CK2b leads to stabilization of both Wee1 and CDC25A. At
present, it is unclear exactly how CK2b regulates CDC25A stability but CK2b presumably enhances CDC25A phosphorylation via
Chk1 and/or other protein kinases. Lack of CK2b, however, leads to partial inhibition of CDK1 and this is explained by the
requirement of CK2b for PLK1–Wee1 interaction. Without CK2b the CK2- and PLK1-dependent Wee1 degradation is compromised,
resulting in stabilization of Wee1 and increased phosphorylation of CDK1.
CK2b regulates the G2/M cell-cycle transition
CW Yde et al
4995
Oncogene
propidium iodide (Sigma, Brndby, Denmark) and 40 mg/ml
RNaseA (Roche, Penzberg, Germany) in PBS prior to analysis
on a FACS-Calibur ﬂow cytometer (Becton-Dickinson,
San Jose, CA, USA). Staining of cells arrested in mitosis with
anti-phospho-histone H3 (Ser10) antibody (Alexa Fluor 488
conjugate; Cell Signaling Technology, Beverly, MA, USA) was
performed according to the manufacturer’s recommendations.
Collected data were analysed by Cell Quest Pro Analysis
software.
Antibodies and immunological methods
Cells were lysed in lysis buffer (50mM Tris/HCl (pH 7.5),
150mM NaCl, 1% Triton X-100, 10% glycerol, 1mM DTT,
1mM Na3VO4, 30mM b-glycerophosphate, 10mM NaF,
100 nM okadaic acid) containing a protease inhibitor cocktail
(Roche). After sonication and centrifugation, whole cell
extracts were subjected to SDS–polyacrylamide gel electro-
phoresis (PAGE), western blot, protein kinase assay or
immunoprecipitation experiments. Proteins were detected by
probing western blot membranes with the following anti-
bodies: mouse monoclonal anti-CK2a, mouse monoclonal
anti-CK2b (both from Calbiochem); rabbit polyclonal anti-
CK2a0 obtained by immunizing rabbits with speciﬁc peptide
sequence of human CK2a0, SQPCADNAVLSSGTAAR;
mouse monoclonal anti-CDC25A, rabbit polyclonal anti-
CDC25C, mouse monoclonal anti-Chk1, mouse monoclonal
anti-CDK1, mouse monoclonal anti-Wee1, rabbit polyclonal
anti-cyclin E, rabbit polyclonal anti-cyclin A, mouse
monoclonal anti-PLK1 antibody (all from Santa Cruz
Biotechnology, Santa Cruz, CA, USA); rabbit polyclonal
anti-phospho-CDK1 (Tyr15), rabbit monoclonal anti-PLK1
(both from Cell Signaling Technology); mouse monoclonal
anti-b-actin (Sigma). Anti-phospho-Wee1 (Ser121) antibody
was raised against phospho-Ser121 peptides, which were also
employed for afﬁnity puriﬁcation; anti-phospho-Wee1 (Ser53)
antibody was as described in Watanabe et al. (2005). Protein–
antibody complexes were visualized by a chemiluminescence
detection system following the manufacturer’s guidelines
(CDP-Star; Applied Biosytems, Foster City, CA, USA).
Unless otherwise indicated, the antibodies employed in the
study detect endogenous levels of total proteins according to
the manufacturers’ speciﬁcations. Densitometric analysis of
the protein bands was performed with Gelwork 1D Inter-
mediate software. Cell lysates were employed for immunopre-
cipitation of PLK1 using rabbit monoclonal anti-PLK1
antibody (Cell Signaling Technology) essentially as previously
described (Guerra et al., 1999).
Protein kinase assays
CK2 kinase assay was performed as previously described
(Guerra et al., 1999) in a reaction mixture containing the CK2-
speciﬁc synthetic peptide RRRDDDSDDD and 10 or 20mg
cell lysate. Immunoprecipitated PLK1 was employed as kinase
source in enzyme assays performed for 20min at 30 1C in a
20 ml reaction mixture containing 50mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (pH 7.5), 10mM MgCl2, 1mM
EDTA, 2mM DTT, 0.01% NP-40, 150mM ATP, 10mCi[g-32P]
ATP and 1mg recombinant puriﬁed GST-MDM2(203282) or
1mg dephosphorylated casein (Sigma). Reactions were termi-
nated by adding sample buffer and boiling for 5min. Proteins
were separated by SDS-PAGE and transferred to polyvinyli-
dene diﬂuoride membranes by western blot. Radioactive
substrates were revealed by autoradiography and radioactivity
was quantiﬁed by scintillation counting (Hewlett-Packard,
Birkerd, Denmark) of the excised radioactive bands. Kinase
assays performed employing 1 pmol recombinant PLK1
(Carna Biosciences, Kobe, Japan) and increasing amounts of
recombinant CK2b were performed as described above.
Purification of recombinant proteins
CK2b was expressed and puriﬁed as described in
(Guerra et al., 2003). GST-MDM2(203282) and GST-
MDM2(203282)(S260A) constructs (the latter contains a
mutation in the target serine phosphorylated by PLK1) were
generated and expressed in bacteria essentially as described in
(Kurki et al., 2004). Pellets from bacteria expressing the
aforementioned proteins were resuspended in sonication buffer
containing 50mM Tris/HCl (pH 8), 300mM NaCl and protease
inhibitor cocktail (Roche). Disruption of the bacteria was
followed by sonication and centrifugation at 4 1C for 30min at
10 000 g. The supernatant was loaded onto a GSH-agarose
column chromatography (Amersham-Biosciences, Hillerd,
Denmark) equilibrated in sonication buffer. After extensive
wash, proteins were eluted in buffer containing 50mM Tris/
HCl (pH 8) and 10mM reduced glutathione (Sigma). Collected
fractions were dialysed overnight in a buffer containing 50mM
Tris/HCl (pH 8), 1mM DTT, 300mM NaCl and 50% glycerol
and stored in aliquots at 70 1C.
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